All In Biotech

Drug Trial Radar · NCT00185419

A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception

An Open-Label, Randomised, Parallel-Group Comparison to Investigate the Efficacy of Yasmin® (30 µg Ethinylestradiol, 3mg Drospirenone) and Marvelon® (30 µg Ethinylestradiol, 150 µg Desogestrel) on Cycle Control in Healthy Chinese Women Over 13 Cycles

Last checked: Nov 20, 2026Latest source record: Jan 14, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 842 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

842

Actual

Start

Nov 2003

Primary completion

Mar 2006

Study completion Mar 2006

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Sep 16, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
Female only, from 20 years, up to 35 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effectiveness in terms of prevention of pregnancy and safety of the oral contraceptive Yasmin and Marvelon on cycle control in healthy Chinese women

Conditions

  • Contraception

Interventions

  • YasminDrug

    30 µg ethinylestradiol, 3mg drospirenone

  • MarvelonDrug

    30 µg ethinylestradiol, 150 µg desogestrel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary efficacy variable is the comparison of cycle control from randomisation to cycle 13. This will be based on the number of subjects reporting at least 1 unexpected intracyclic bleeding episode between cycles 2 to 13.Time frame: 13 treatment cycles (1 cycle= 28 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Ask Contact, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.